Juan Carlos Lacal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3309271/publications.pdf

Version: 2024-02-01

117	6,406	47006	69250
papers	citations	47 h-index	77 g-index

119	119	119	6360
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochemical and Biophysical Research Communications, 2002, 296, 580-583.	2.1	326
2	Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha-ras oncogene. Nature, 1987, 330, 269-272.	27.8	312
3	Rho signals to cell growth and apoptosis. Cancer Letters, 2001, 165, 1-10.	7.2	288
4	Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene, 2002, 21, 4317-4322.	5.9	232
5	Rho GTPase expression in tumourigenesis: Evidence for a significant link. BioEssays, 2005, 27, 602-613.	2.5	211
6	Multiple Signalling Pathways Lead to the Activation of the Nuclear Factor Î¹B by the Rho Family of GTPases. Journal of Biological Chemistry, 1998, 273, 12779-12785.	3.4	208
7	Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene, 1997, 15, 2289-2301.	5.9	155
8	Rho proteins induce metastatic properties in vivo. Oncogene, 1997, 15, 3047-3057.	5.9	153
9	Orthotopic Microinjection of Human Colon Cancer Cells in Nude Mice Induces Tumor Foci in All Clinically Relevant Metastatic Sites. American Journal of Pathology, 2007, 170, 1077-1085.	3.8	140
10	Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncology, The, 2007, 8, 889-897.	10.7	140
11	Choline Uptake and Metabolism Modulate Macrophage IL-1Î² and IL-18 Production. Cell Metabolism, 2019, 29, 1350-1362.e7.	16.2	140
12	Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of the Choline Kinase Inhibitor MN58b in Human Carcinoma Models. Cancer Research, 2006, 66, 427-434.	0.9	135
13	Ras p21 proteins with high or low GTPase activity can efficiently transform NIH3T3 cells. Cell, 1986, 44, 609-617.	28.9	128
14	Choline Kinase Activation Is a Critical Requirement for the Proliferation of Primary Human Mammary Epithelial Cells and Breast Tumor Progression. Cancer Research, 2004, 64, 6732-6739.	0.9	118
15	New Analogues of Amonafide and Elinafide, Containing Aromatic Heterocycles:Â Synthesis, Antitumor Activity, Molecular Modeling, and DNA Binding Properties. Journal of Medicinal Chemistry, 2004, 47, 1391-1399.	6.4	116
16	Regulation of choline kinase activity by Ras proteins involves Ralâ€“GDS and PI3K. Oncogene, 2002, 21, 937-946.	5.9	114
17	18 F-Choline Images Murine Atherosclerotic Plaques Ex Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 584-589.	2.4	111
18	Rho GTPases: potential candidates for anticancer therapy. Cancer Letters, 2004, 206, 181-191.	7.2	106

#	Article	IF	Citations
19	Simultaneous Tyrosine and Serine Phosphorylation of STAT3 Transcription Factor Is Involved in Rho A GTPase Oncogenic Transformation. Molecular Biology of the Cell, 2001, 12, 3282-3294.	2.1	101
20	Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but Bcl2 dependent pathway. Oncogene, 1998, 17, 1855-1869.	5.9	92
21	Cell Stress and MEKK1-mediated c-Jun Activation Modulate NFÎºB Activity and Cell Viability. Molecular Biology of the Cell, 2002, 13, 2933-2945.	2.1	92
22	Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. Journal of Cellular Biochemistry, 1995, 57, 141-149.	2.6	89
23	Differential Role of Human Choline Kinase Î± and Î² Enzymes in Lipid Metabolism: Implications in Cancer Onset and Treatment. PLoS ONE, 2009, 4, e7819.	2.5	88
24	Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1705, 121-132.	7.4	82
25	Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene, 2003, 22, 8803-8812.	5.9	81
26	Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene, 2004, 23, 8247-8259.	5.9	81
27	Activation of Serum Response Factor by RhoA Is Mediated by the Nuclear Factor-ÎºB and C/EBP Transcription Factors. Journal of Biological Chemistry, 1999, 274, 8506-8515.	3.4	80
28	Choline Kinase Is a Novel Oncogene that Potentiates RhoA-Induced Carcinogenesis. Cancer Research, 2005, 65, 5647-5653.	0.9	77
29	ROCK and Nuclear Factor-ÎºBâ€“dependent Activation of Cyclooxygenase-2 by Rho GTPases: Effects on Tumor Growth and Therapeutic Consequences. Molecular Biology of the Cell, 2003, 14, 3041-3054.	2.1	76
30	Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: Implications in cancer therapy. International Journal of Biochemistry and Cell Biology, 2008, 40, 1753-1763.	2.8	74
31	Apoptosis Induced by Rac GTPase Correlates with Induction of FasL and Ceramides Production. Molecular Biology of the Cell, 2000, 11, 4347-4358.	2.1	69
32	TWIST1 Overexpression is Associated with Nodal Invasion and Male Sex in Primary Colorectal Cancer. Annals of Surgical Oncology, 2009, 16, 78-87.	1.5	68
33	Choline kinase inhibition in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1399-1407.	0.9	64
34	Choline kinase inhibition induces exacerbated endoplasmic reticulum stress and triggers apoptosis via CHOP in cancer cells. Cell Death and Disease, 2013, 4, e933-e933.	6.3	63
35	Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid-dependent signaling. FEBS Letters, 1997, 410, 73-77.	2.8	58
36	Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells. Molecular Cancer, 2009, 8, 131.	19.2	58

#	Article	IF	Citations
37	The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase Î± Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy. Cancer Research, 2010, 70, 5507-5517.	0.9	58
38	Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma. Oncotarget, 2016, 7, 12582-12597.	1.8	58
39	Loss of mouse fibroblast cell response to phorbol esters restored by microinjected protein kinase C. Nature, 1986, 324, 375-377.	27.8	55
40	A critical role for choline kinase-Î± in the aggressiveness of bladder carcinomas. Oncogene, 2009, 28, 2425-2435.	5.9	55
41	Symmetrical Bis-Quinolinium Compounds:Â New Human Choline Kinase Inhibitors with Antiproliferative Activity against the HT-29 Cell Line. Journal of Medicinal Chemistry, 2005, 48, 3354-3363.	6.4	53
42	Preclinical Characterization of RSM-932A, a Novel Anticancer Drug Targeting the Human Choline Kinase Alpha, an Enzyme Involved in Increased Lipid Metabolism of Cancer Cells. Molecular Cancer Therapeutics, 2015, 14, 31-39.	4.1	53
43	A Critical Role for Rac1 in Tumor Progression of Human Colorectal Adenocarcinoma Cells. American Journal of Pathology, 2008, 172, 156-166.	3.8	52
44	Choline Kinase Alpha Depletion Selectively Kills Tumoral Cells. Current Cancer Drug Targets, 2008, 8, 709-719.	1.6	52
45	Involvement of human choline kinase alpha and beta in carcinogenesis: A different role in lipid metabolism and biological functions. Advances in Enzyme Regulation, 2011, 51, 183-194.	2.6	51
46	Signaling from G Protein-coupled Receptors to the c-jun Promoter Involves the MEF2 Transcription Factor. Journal of Biological Chemistry, 1997, 272, 20691-20697.	3.4	50
47	Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. International Journal of Oncology, 2008, 33, 185-93.	3.3	49
48	Phosphorylation of ras oncogene product by protein kinase C. Biochemical and Biophysical Research Communications, 1987, 145, 782-788.	2.1	46
49	Relationship between Membrane Integrity and the Inhibition of Host Translation in Virus-Infected Mammalian Cells. Comparative Studies between Encephalomyocarditis Virus and Poliovirus. FEBS Journal, 1982, 127, 359-366.	0.2	45
50	Micro-injection of recombinant lysyl oxidase blocks oncogenic p21-Ha-Ras and progesterone effects onXenopus laevisoocyte maturation. FEBS Letters, 1997, 419, 63-68.	2.8	45
51	Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Oncogene, 2001, 20, 1110-1117.	5.9	44
52	Inhibition of ChoK Is an Efficient Antitumor Strategy for Harvey-, Kirsten-, and N-ras-Transformed Cells. Biochemical and Biophysical Research Communications, 2001, 285, 873-879.	2.1	42
53	Screening for new compounds with antiherpes activity. Antiviral Research, 1984, 4, 231-244.	4.1	41
54	Combined 5-FU and ChoKÎ± Inhibitors as a New Alternative Therapy of Colorectal Cancer: Evidence in Human Tumor-Derived Cell Lines and Mouse Xenografts. PLoS ONE, 2013, 8, e64961.	2.5	41

#	Article	IF	Citations
55	Antibiotics that specifically block translation in virus-infected cells.. Journal of Antibiotics, 1980, 33, 441-446.	2.0	39
56	STAT5a Activation Mediates the Epithelial to Mesenchymal Transition Induced by Oncogenic RhoA.. Molecular Biology of the Cell, 2003, 14, 40-53.	2.1	39
57	Identification of rho as a substrate for botulinum toxin C3 -catalyzed ADP-ribosylation. FEBS Letters, 1989, 247, 221-226.	2.8	37
58	Searching new targets for anticancer drug design: The families of Ras and Rho GTPases and their effectors. Progress in Molecular Biology and Translational Science, 2001, 67, 193-234.	1.9	36
59	From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Letters, 2004, 206, 137-148.	7.2	36
60	Permeabilization of cells during animal virus infection. , 1983, 23, 109-145.		35
61	LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase. European Journal of Medicinal Chemistry, 2001, 36, 215-225.	5.5	34
62	Quantitative structureâ€“activity relationships for a series of symmetrical bisquaternary anticancer compounds. Bioorganic and Medicinal Chemistry, 2002, 10, 2215-2231.	3.0	34
63	ras-p21 Activates phospholipase D and A2, but not phospholipase C or PKC, inXenopus laevis Oocytes. Journal of Cellular Biochemistry, 1994, 54, 478-486.	2.6	33
64	Analysis of the rasH oncogene and its p21 product in chemically induced skin tumors and tumor-derived cell lines. Carcinogenesis, 1987, 8, 1821-1825.	2.8	32
65	QSAR-Derived Choline Kinase Inhibitors: How Rational can Antiproliferative Drug Design Be?. Current Medicinal Chemistry, 2003, 10, 1095-1112.	2.4	31
66	Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics. Clinical and Translational Oncology, 2011, 13, 617-628.	2.4	31
67	Differential effects of phorbol ester on the in vitro invasiveness of malignant and non-malignant human fibroblast cells. Journal of Cellular Physiology, 1990, 142, 55-60.	4.1	30
68	Phospholipase-induced maturation ofXenopus laevis oocytes: Mitogenic activity of generated metabolites. Journal of Cellular Biochemistry, 1993, 52, 440-448.	2.6	30
69	Influence of the Linker in Bispyridium Compounds on the Inhibition of Human Choline Kinase. Journal of Medicinal Chemistry, 2004, 47, 5433-5440.	6.4	29
70	Localization of rap1 and rap2 proteins in the gelatinase-containing granules of human neutrophils. FEBS Letters, 1993, 326, 209-214.	2.8	28
71	Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer. International Journal of Biochemistry and Cell Biology, 2007, 39, 2289-2302.	2.8	27
72	Activation of phospholipase D by growth factors and oncogenes in murine fibroblasts follow alternative but cross-talking pathways. Biochemical Journal, 1997, 322, 519-528.	3.7	26

#	Article	IF	Citations
73	Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes. International Journal of Cancer, 1995, 60, 235-243.	5.1	26
74	Choline Kinase Alpha (CHKÎ±) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. Molecular Cancer Therapeutics, 2016, 15, 323-333.	4.1	25
75	Antiplasmodial Activity and Mechanism of Action of RSM-932A, a Promising Synergistic Inhibitor of Plasmodium falciparum Choline Kinase. Antimicrobial Agents and Chemotherapy, 2013, 57, 5878-5888.	3.2	24
76	Agonist-induced phosphorylation of an immunologically ras-related protein in human erythroleukemia cells. Biochemical and Biophysical Research Communications, 1989, 161, 972-978.	2.1	23
77	Choline kinase inhibitory effect and antiproliferative activity of new 1,1â€²,1â€³-(benzene-1,3,5-triylmethylene)tris?4-[(disubstituted)amino]pyridinium? tribromides. European Journal of Medicinal Chemistry, 2003, 38, 109-116.	5.5	22
78	Ras protein is involved in the physiological regulation of phospholipase D by platelet derived growth factor. Oncogene, 2000, 19, 431-437.	5.9	21
79	Human urine proteomics: building a list of human urine cancer biomarkers. Expert Review of Proteomics, 2011, 8, 347-360.	3.0	21
80	Progesterone but notras requires MPF for in vivo activation of MAPK and S6 KII: MAPK is an essential conexion point of both signaling pathways. Journal of Cellular Biochemistry, 1994, 55, 465-476.	2.6	19
81	Lights and shadows of proteomic technologies for the study of protein species including isoforms, splicing variants and protein postâ€translational modifications. Proteomics, 2011, 11, 590-603.	2.2	19
82	Upregulation of Trefoil Factor 3 (TFF3) After Rectal Cancer Chemoradiotherapy Is an Adverse Prognostic Factor and a Potential Therapeutic Target. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1151-1158.	0.8	19
83	Wortmannin, an inhibitor of phosphatidyl-inositol 3-kinase, induces oocyte maturation through a MPF-MAPK-dependent pathway. FEBS Letters, 1998, 422, 155-159.	2.8	18
84	Activation of phospholipase D by ras proteins is independent of protein kinase C. , 1996, 61, 599-608.		17
85	A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products. Clinical and Translational Oncology, 2015, 17, 74-84.	2.4	14
86	Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets. Progress in Cell Cycle Research, 2003, 5, 191-201.	0.9	14
87	Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. International Journal of Oncology, 2005, 26, 999-1008.	3.3	14
88	Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer. Oncotarget, 2017, 8, 26755-26770.	1.8	12
89	Choline Kinase: An Unexpected Journey for a Precision Medicine Strategy in Human Diseases. Pharmaceutics, 2021, 13, 788.	4.5	11
90	Conformational alterations detected by circular dichroism induced in the normal ras p21 protein by activating point mutations at position 12, 59, or 61. FEBS Journal, 1988, 174, 621-627.	0.2	10

#	Article	IF	Citations
91	Protein chimerism: Novel source of protein diversity in humans adds complexity to bottomâ€up proteomics. Proteomics, 2013, 13, 5-11.	2.2	10
92	Choline Kinase Emerges as a Promising Drug Target in Gram-Positive Bacteria. Frontiers in Microbiology, 2019, 6, 2146.	3.5	10
93	Microinjection of acylphosphatase blocksXenopus laevisoocytes maturation induced byras-p21. FEBS Letters, 1993, 326, 167-170.	2.8	7
94	Rho GTPases in human carcinogenesis: a tale of excess. , 2003, 5, 70-78.		7
95	Acylphosphatase synergizes with progesterone during maturation ofXenopus laevisoocytes. FEBS Letters, 1993, 327, 265-270.	2.8	6
96	Generation and characterization of monoclonal antibodies against choline kinase alpha and their potential use as diagnostic tools in cancer. International Journal of Oncology, 2006, 29, 335-40.	3.3	6
97	Sensitization of (colon) cancer cells to death receptor related therapies. Cancer Biology and Therapy, 2012, 13, 458-466.	3.4	4
98	Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility. Clinical and Translational Oncology, 2014, 16, 107-112.	2.4	4
99	Identification and validation of novel and more effective choline kinase inhibitors against Streptococcus pneumoniae. Scientific Reports, 2020, 10, 15418.	3.3	4
100	Changing the course of oncogenesis: The development of tyrosine kinase inhibitors. European Journal of Cancer, Supplement, 2006, 4, 14-20.	2.2	3
101	Biological Function of Aplysia californica rho Gene. , 1991, , 237-242.		3
102	A dual choline/phosphocholine colorimetric method for measuring the relative strength of inhibitors of choline kinases of Gram-positive pathogens. Food Science and Applied Biotechnology, 2018, 1, 131.	0.6	3
103	New Editorial Board for Clinical and Translational Oncology. Clinical and Translational Oncology, 2009, 11, 1-1.	2.4	2
104	GTPase. , 2011, , 1609-1613.		2
105	Rho proteins in the regulation of apoptosis. Biology of the Cell, 1999, 91, 549-550.	2.0	1
106	Bad patients meet good drugs. Clinical and Translational Oncology, 2006, 8, 225-227.	2.4	1
107	Regulation of choline kinase activity by Ras proteins involves Ralâ€“GDS and PI3K. , 0, .		1
108	Rapid Stimulation of Diacylglycerol Production in Xenopus Oocytes by Microinjection of H-ras p21. Obstetrical and Gynecological Survey, 1988, 43, 417.	0.4	0

#	Article	IF	Citations
109	Anticancer research: a few hints for discovery of new targets. Cancer Letters, 2004, 206, 125-127.	7.2	0
110	It is about time that spain launches a National Cancer Act?. Clinical and Translational Oncology, 2006, 8, 841-842.	2.4	0
111	FESEO and Clinical & Translational Oncology: a brief historical perspective. Clinical and Translational Oncology, 2008, 10, 683-684.	2.4	0
112	Clinical and Translational Oncology accepted in SciSearchÂ® and Journal Citation Reports. Clinical and Translational Oncology, 2008, 10, 773-773.	2.4	0
113	Biological Methods for Metabolic Research. , 0, , 54-76.		0
114	Analysis of the Biochemical and Biological Activities of Deletion Mutants of the H-Ras P21 Protein Suggest That Gap is an Essential Component of Its Effector Function. , 1989, , 179-190.		0
115	Ras Proteins as Potential Activators of Protein Kinase C Function. , 1989, , 105-118.		0
116	GTPase. , 2016, , 1968-1973.		0
117	Choline Kinase Î± Inhibitors MN58b and RSM932A Enhances the Antitumor Response to Cisplatin in Lung Tumor Cells. Pharmaceutics, 2022, 14, 1143.	4.5	0